250 biomarkers, standard serum sample, seven minutes: deploying AI-driven metabolomics for preventive care at scale across clinical and pharmacy settings

Problem: A standard check-up measures 20-30 biomarkers in isolation and calls it prevention – missing the metabolic patterns that precede disease by years. NCDs are accelerating, clinical capacity is shrinking, and the tools most physicians rely on have not changed in decades.

Implemented Solution: We deployed our engine pairing NMR spectroscopy with proprietary AI to generate multi-dimensional health assessments from a blood sample. One seven-minute measurement, no pre-treatment, about 250 biomarkers – analyzed as an integrated metabolic fingerprint. Our MetaboPRO models translate this into risk profiles across glycemic control, liver and kidney function, inflammation, and cardiovascular risk. Live in European physician practices and German pharmacies – metabolomics-driven prevention with professional consultation at point of access.

Governance: GDPR-compliant, pseudonymized processing in a secured cloud. CE certification underway for 2026. Reference: over 275,000 curated metabolomic profiles stratified by age and sex.

Outcomes: Since 2025, adoption has grown across clinical sites and international labs. Clinicians value detecting system-wide metabolic shifts – especially longitudinally – that single-marker panels miss. Atypical constellations have triggered earlier follow-up uncovering systemic conditions. Minimal wet-lab changes; turnaround in hours.

Lessons Learned: Three adoption drivers: (1) pattern-level interpretation – clinicians want context, not numbers; (2) decision-support framing rather than diagnosis, resolving regulatory ambiguity; (3) local partners who know pharmacy and physician workflows. The hardest challenge was cultural: convincing immunoassay-trained clinicians to trust a physical measurement analyzed by complex software.

Recommendations: Evidence first, not marketing. Regulatory clarity before scale. Interpretability over impressiveness. Prevention at scale needs technology that fits how decisions are actually made – not how we wish they were.